San Diego-based Anadys Pharmaceuticals (NASDAQ: [[ticker:ANDS]]) said today it has gotten the green light from the FDA to start a mid-stage clinical trial of its experimental hepatitis C drug, ANA598, in combination with the standard treatments, pegylated inferferon alpha and ribavirin. About 90 patients are expected to enroll, with the first joining the study within weeks, the company said. Anadys, which hopes this drug candidate will alter the standard of care for hepatitis C, expects to receive the first results from this study as soon as the end of the year.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
